Molnupiravir (MOV) is an orally administered ribonucleoside prodrug of β-D-N4-hydroxycytidine (NHC) which acts against SARS-CoV-2. A viral dynamics analysis of Phase 2 clinical virology data assisted MOV Phase 3 study design and development strategy.

The development of an Immune-Viral Dynamics Model (IVDM) was done with mechanisms of SARS-CoV-2 infection, replication, and induced immunity, which together represent the dynamics of viral load (VL) during disease progression. Longitudinal virology data from ferret studies were used to inform IVDM, which was also translated to humans by adjusting parameter values to capture clinical data from MOVe-IN/MOVe-OUT studies. Different placements of drug effects (on viral infectivity vs. productivity) and representations of immune response were investigated. A simplified 95% drug effect was enforced to depict a highly effective dose of MOV.

The following results were obtained-

• IVDM demonstrated that data were best explained when MOV acts on viral infectivity, consistent with the error catastrophe mechanism of action. 
• A cascade of innate and adaptive immune response and a basal level activation promoted durable immunity and continued viral decay after the end of treatment. 
• IVDM well illustrates VL and viral titer data from animals and humans. 
• The influence of MOV start time was investigated using simulations. Similar to ferret studies, simulations showed when treatment is initiated within the first-week post-infection, MOV decreases viral growth, causing a lower and shortened duration of detectable VL. 
• When initiated later (e.g. >7 days since symptom onset), the magnitude of drug effect is markedly diminished in a typical patient with an effective immune response that reduces VL before treatment starts. 
• Further work is needed to illustrate response in patients with longer-term infection, where MOV drug effects may have more constant utility.

This COVID-19 IVDM designed using multiscale MOV virology data backs drug action on viral infectivity and the importance of the interplay of treatment and immune response and can describe infection time course and drug effect. IVDM supplied mechanistic interpretations for VL drug effect in clinical studies.

Source- Open Forum Infectious Diseases. 2021 Nov;8(1):S362-S363. PMCID: PMC8644542.